Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Email this article to a Colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Articles & Searches Download to citation manager Citing Articles via HighWire Citing Articles via Google Scholar Articles by Fenton, W. S. Articles by Knable, M. Search for Related Content PubMed Citation Articles by Fenton, W. S. Articles by Knable, M. Neurophysiology Schizophrenia Spectrum Disorders Other Somatic Therapy Cognition

A Placebo-Controlled Trial of Omega-3 Fatty Acid (Ethyl Eicosapentaenoic Acid) Supplementation for Residual Symptoms and Cognitive Impairment in Schizophrenia

OBJECTIVE: This study determined if augmentation of neuroleptics with 3 g/day of ethyl eicosapentaenoic acid (EPA) improves symptoms and cognition in patients with schizophrenia or schizoaffective disorder. METHOD: Eighty-seven patients meeting criteria for schizophrenia or schizoaffective disorder who had residual symptoms despite neuroleptic treatment were randomly assigned to receive either 3 g/day of ethyl EPA (N=43) or placebo (N=44) in a 16-week, double-blind supplementation trial. Assessments were performed at baseline and at weeks 1, 2, 4, 8, 12, and 16; a cognitive battery was administered at baseline and at week 16. RESULTS: No differences were found between groups in positive or negative symptoms, mood, cognition, or global impression ratings. Results were similar for the intention-to-treat (N=87) and completer (N=75) groups. CONCLUSIONS: For schizophrenia patients treated with 3 g/day of ethyl EPA, improvement in residual symptoms and cognitive impairment was no greater than for schizophrenia patients treated with placebo.

This article has been cited by other articles:

				D. A. Lewis, R. Y. Cho, C. S. Carter, K. Eklund, S. Forster, M. A. Kelly, and D. Montrose Subunit-Selective Modulation of GABA Type A Receptor Neurotransmission and Cognition in Schizophrenia Am J Psychiatry, December 1, 2008; 165(12): 1585 - 1593. [Abstract] [Full Text] [PDF]

				K. M Appleton, R. C Hayward, D. Gunnell, T. J Peters, P. J Rogers, D. Kessler, and A. R Ness Effects of n-3 long-chain polyunsaturated fatty acids on depressed mood: systematic review of published trials Am. J. Clinical Nutrition, December 1, 2006; 84(6): 1308 - 1316. [Abstract] [Full Text] [PDF]

				S. Lee, K. M. Gura, S. Kim, D. A. Arsenault, B. R. Bistrian, and M. Puder Current Clinical Applications of {Omega}-6 and {Omega}-3 Fatty Acids Nutr Clin Pract, August 1, 2006; 21(4): 323 - 341. [Abstract] [Full Text] [PDF]

				S. Noaghiul and J. R. Hibbeln Cross-National Comparisons of Seafood Consumption and Rates of Bipolar Disorders Am J Psychiatry, December 1, 2003; 160(12): 2222 - 2227. [Abstract] [Full Text] [PDF]

				F. B. Dickerson, J. J. Boronow, C. Stallings, A. E. Origoni, I. Ruslanova, and R. H. Yolken Association of Serum Antibodies to Herpes Simplex Virus 1 With Cognitive Deficits in Individuals With Schizophrenia Arch Gen Psychiatry, May 1, 2003; 60(5): 466 - 472. [Abstract] [Full Text] [PDF]

				D. F. HORROBIN Omega-3 Fatty Acid for Schizophrenia Am J Psychiatry, January 1, 2003; 160(1): 188 - 189. [Full Text]

				C. M. Wilk, J. M. Gold, J. J. Bartko, F. Dickerson, W. S. Fenton, M. Knable, C. Randolph, and R. W. Buchanan Test-Retest Stability of the Repeatable Battery for the Assessment of Neuropsychological Status in Schizophrenia Am J Psychiatry, May 1, 2002; 159(5): 838 - 844. [Abstract] [Full Text] [PDF]

				M. Peet Essential fatty acids: theoretical aspects and treatment implications for schizophrenia and depression Adv. Psychiatr. Treat., May 1, 2002; 8(3): 223 - 229. [Full Text] [PDF]

Get information about faster international access.

Privacy Policy

Copyright © 2001 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us